An international research group directed by UMC Utrecht has developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI. Their findings open ...
An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI. Their findings open ...
An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI. Their findings open ...
To choose the best lead candidates during drug and antibody screening, scientists characterize a molecule’s binding properties, such as kinetics and affinity. Robust assay design reduces experimental ...
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
A review of the phase III SOPHIA trial on margetuximab vs trastuzumab for the treatment of relapsed/refractory HER2+ metastatic breast cancer. Transcript Hope S. Rugo, MD: I wanted to mention the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback